Status:

ACTIVE_NOT_RECRUITING

Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients

Lead Sponsor:

Mayo Clinic

Conditions:

Anatomic Stage I Breast Cancer AJCC v8

Anatomic Stage II Breast Cancer AJCC v8

Eligibility:

FEMALE

18+ years

Phase:

PHASE3

Brief Summary

This phase III trial compares the rate of complications of x-ray therapy versus proton beam radiation therapy after breast conserving surgery or mastectomy in treating patients with breast cancer. X-r...

Detailed Description

PRIMARY OBJECTIVE: I. To determine the 24-month complication rate of 5 fraction radiotherapy compared to 25 fraction radiotherapy. SECONDARY OBJECTIVES: I. To evaluate acute toxicity that occur up ...

Eligibility Criteria

Inclusion

  • Age \>= 18 years
  • Histological confirmation of breast cancer
  • Breast conserving surgery or mastectomy (reconstruction is allowed)
  • Clinical or pathologic T1-T4c, N0-3, M0 disease
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2
  • Able to and provides Institutional Review Board (IRB) approved study specific written informed consent
  • Indications for breast or post mastectomy radiation with regional nodal radiotherapy per the discretion of the treating physician
  • If uncertain of eligibility please consult the principal investigator (PI)

Exclusion

  • Medical contraindication to receipt of radiotherapy
  • Severe active co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator or PI, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or providing informed consent
  • Active systemic lupus or scleroderma
  • Prior receipt of ipsilateral breast or chest wall radiation
  • Persistent positive margins on ink after definitive surgery either for ductal carcinoma in situ (DCIS) or invasive cancer
  • No active metastatic disease from other origin
  • Recurrent breast cancer
  • Patient requires bilateral breast radiation treatment
  • cT4d patients (inflammatory breast cancer)
  • Patients that may not be compliant or fit for the study at the discretion of the PI
  • Male patients

Key Trial Info

Start Date :

June 16 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 19 2029

Estimated Enrollment :

146 Patients enrolled

Trial Details

Trial ID

NCT04443413

Start Date

June 16 2020

End Date

November 19 2029

Last Update

August 13 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Mayo Clinic in Arizona

Scottsdale, Arizona, United States, 85259

2

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224-9980

3

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905